Assembly Biosciences (NASDAQ:ASMB – Free Report) had its price target increased by Guggenheim from $39.00 to $43.00 in a research report sent to investors on Monday morning,Benzinga reports. Guggenheim currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also issued reports on the stock. HC Wainwright […]

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eight analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to […]